| 摘要 |
NZ 601913 Disclosed is the use of a spray-dried powder comprising adalimumab, or an antigen-binding fragment thereof, and an excipient, for the manufacture of a medicament for treating a subject having a disorder selected from the group consisting of an autoimmune disease, an intestinal disorder, a spondyloarthropathy, and a skin disorder, wherein the powder has a residual moisture of less than 6% (wt %) and is stable at ambient temperatures and humidity for at least three months. |
